Design considerations in an active medical product safety monitoring system

被引:38
作者
Gagne, Joshua J. [1 ]
Fireman, Bruce [3 ]
Ryan, Patrick B. [4 ]
Maclure, Malcolm [5 ,6 ]
Gerhard, Tobias [7 ]
Toh, Sengwee [2 ]
Rassen, Jeremy A. [1 ]
Nelson, Jennifer C. [8 ,9 ]
Schneeweiss, Sebastian [1 ]
机构
[1] Brigham & Womens Hosp, Div Pharmacoepidemiol & Pharmacoecon, Dept Med, Boston, MA 02120 USA
[2] Harvard Univ, Dept Populat Med, Sch Med, Boston, MA USA
[3] Kaiser Permanente No Calif, Div Res, Oakland, CA USA
[4] Johnson & Johnson, Titusville, NJ USA
[5] Univ British Columbia, Dept Anesthesiol Pharmacol & Therapeut, Vancouver, BC V5Z 1M9, Canada
[6] BC Minist Hlth Serv, Pharmaceut Serv Div, Victoria, BC, Canada
[7] Rutgers State Univ, Ernest Mario Sch Pharm, New Brunswick, NJ 08903 USA
[8] Grp Hlth Res Inst, Biostat Unit, Seattle, WA USA
[9] Univ Washington, Dept Biostat, Seattle, WA 98195 USA
关键词
study design; safety monitoring; pharmacoepidemiology; exposure characteristics; outcome characteristics; SUDDEN CARDIAC DEATH; ACUTE MYOCARDIAL-INFARCTION; MARGINAL STRUCTURAL MODELS; CORONARY-HEART-DISEASE; CASE-CROSSOVER DESIGN; CAUSAL INFERENCE; VACCINE SAFETY; CASE SERIES; RISK; COHORT;
D O I
10.1002/pds.2316
中图分类号
R1 [预防医学、卫生学];
学科分类号
1004 ; 120402 ;
摘要
Active medical product monitoring systems, such as the Sentinel System, will utilize electronic healthcare data captured during routine health care. Safety signals that arise from these data may be spurious because of chance or bias, particularly confounding bias, given the observational nature of the data. Applying appropriate monitoring designs can filter out many false-positive and false-negative associations from the outset. Designs can be classified by whether they produce estimates based on between-person or within-person comparisons. In deciding which approach is more suitable for a given monitoring scenario, stakeholders must consider the characteristics of the monitored product, characteristics of the health outcome of interest (HOI), and characteristics of the potential link between these. Specifically, three factors drive design decisions: (i) strength of within-person and between-person confounding; (ii) whether circumstances exist that may predispose to misclassification of exposure or misclassification of the timing of the HOI; and (iii) whether the exposure of interest is predominantly transient or sustained. Additional design considerations include whether to focus on new users, the availability of appropriate active comparators, the presence of an exposure time trend, and the measure of association of interest. When the key assumptions of self-controlled designs are fulfilled (i.e., lack of within-person, time-varying confounding; abrupt HOI onset; and transient exposure), within-person comparisons are preferred because they inherently avoid confounding by fixed factors. The cohort approach generally is preferred in other situations and particularly when timing of exposure or outcome is uncertain because cohort approaches are less vulnerable to biases resulting from misclassification. Copyright (C) 2012 John Wiley & Sons, Ltd.
引用
收藏
页码:32 / 40
页数:9
相关论文
共 52 条
[1]   In defense of pharmacoepidemiology - Embracing the yin and yan of drug research [J].
Avorn, Jerry .
NEW ENGLAND JOURNAL OF MEDICINE, 2007, 357 (22) :2219-2221
[2]   Managing Drug-Risk Information - What to Do with All Those New Numbers [J].
Avorn, Jerry ;
Schneeweiss, Sebastian .
NEW ENGLAND JOURNAL OF MEDICINE, 2009, 361 (07) :647-649
[3]   Instrumental variable methods in comparative safety and effectiveness research [J].
Brookhart, M. Alan ;
Rassen, Jeremy A. ;
Schneeweiss, Sebastian .
PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2010, 19 (06) :537-554
[4]   Confounder summary scores when comparing the effects of multiple drug exposures [J].
Cadarette, Suzanne M. ;
Gagne, Joshua J. ;
Solomon, Daniel H. ;
Katz, Jeffrey N. ;
Stuermer, Til .
PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2010, 19 (01) :2-9
[5]   Effect of highly active antiretroviral therapy on time to acquired immunodeficiency syndrome or death using marginal structural models [J].
Cole, SR ;
Hernán, MA ;
Robins, JM ;
Anastos, K ;
Chmiel, J ;
Detels, R ;
Ervin, C ;
Feldman, J ;
Greenblatt, R ;
Kingsley, L ;
Lai, SH ;
Young, M ;
Cohen, M ;
Muñoz, A .
AMERICAN JOURNAL OF EPIDEMIOLOGY, 2003, 158 (07) :687-694
[6]   Illustrating bias due to conditioning on a collider [J].
Cole, Stephen R. ;
Platt, Robert W. ;
Schisterman, Enrique F. ;
Chu, Haitao ;
Westreich, Daniel ;
Richardson, David ;
Poole, Charles .
INTERNATIONAL JOURNAL OF EPIDEMIOLOGY, 2010, 39 (02) :417-420
[7]   Use of a claims-based active drug safety surveillance system to assess the risk of acute pancreatitis with exenatide or sitagliptin compared to metformin or glyburide [J].
Dore, David D. ;
Seeger, John D. ;
Chan, K. Arnold .
CURRENT MEDICAL RESEARCH AND OPINION, 2009, 25 (04) :1019-1027
[8]   Supplementary data collection with case-cohort analysis to address potential confounding in a cohort study of thromboembolism in oral contraceptive initiators matched on claims-based propensity scores [J].
Eng, P. Mona ;
Seeger, John D. ;
Loughlin, Jeanne ;
Clifford, C. Robin ;
Mentor, Sherry ;
Walker, Alexander M. .
PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2008, 17 (03) :297-305
[9]   RELATIVE INCIDENCE ESTIMATION FROM CASE SERIES FOR VACCINE SAFETY EVALUATION [J].
FARRINGTON, CP .
BIOMETRICS, 1995, 51 (01) :228-235
[10]   MEDICAID RECORDS AS A VALID DATA SOURCE - TENNESSEE EXPERIENCE [J].
FEDERSPIEL, CF ;
RAY, WA ;
SCHAFFNER, W .
MEDICAL CARE, 1976, 14 (02) :166-172